全文获取类型
收费全文 | 3770篇 |
免费 | 264篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 185篇 |
妇产科学 | 48篇 |
基础医学 | 445篇 |
口腔科学 | 90篇 |
临床医学 | 324篇 |
内科学 | 719篇 |
皮肤病学 | 35篇 |
神经病学 | 273篇 |
特种医学 | 301篇 |
外科学 | 695篇 |
综合类 | 57篇 |
一般理论 | 5篇 |
预防医学 | 260篇 |
眼科学 | 63篇 |
药学 | 176篇 |
中国医学 | 1篇 |
肿瘤学 | 310篇 |
出版年
2021年 | 43篇 |
2020年 | 27篇 |
2019年 | 46篇 |
2018年 | 45篇 |
2016年 | 37篇 |
2015年 | 43篇 |
2014年 | 63篇 |
2013年 | 116篇 |
2012年 | 127篇 |
2011年 | 146篇 |
2010年 | 103篇 |
2009年 | 86篇 |
2008年 | 137篇 |
2007年 | 147篇 |
2006年 | 125篇 |
2005年 | 138篇 |
2004年 | 131篇 |
2003年 | 127篇 |
2002年 | 122篇 |
2001年 | 105篇 |
2000年 | 128篇 |
1999年 | 97篇 |
1998年 | 69篇 |
1997年 | 52篇 |
1996年 | 58篇 |
1995年 | 52篇 |
1994年 | 56篇 |
1993年 | 45篇 |
1992年 | 102篇 |
1991年 | 95篇 |
1990年 | 84篇 |
1989年 | 108篇 |
1988年 | 95篇 |
1987年 | 106篇 |
1986年 | 96篇 |
1985年 | 100篇 |
1984年 | 58篇 |
1983年 | 60篇 |
1982年 | 33篇 |
1981年 | 35篇 |
1980年 | 43篇 |
1979年 | 58篇 |
1978年 | 38篇 |
1977年 | 57篇 |
1976年 | 43篇 |
1975年 | 47篇 |
1974年 | 43篇 |
1973年 | 31篇 |
1972年 | 35篇 |
1970年 | 26篇 |
排序方式: 共有4041条查询结果,搜索用时 15 毫秒
61.
Ewing's sarcoma/primitive neuroectodermal tumor of the ureter: a case report and review of the literature 总被引:5,自引:0,他引:5
Charny CK Glick RD Genega EM Meyers PA Reuter VE La Quaglia MP 《Journal of pediatric surgery》2000,35(9):1356-1358
Extraosseous Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) is a rare soft tissue tumor of childhood usually found in the extremities. The authors present the case of a 17-year-old girl who presented with right flank pain and hematuria and during operation was found to have a right ureteral mass. The histopathologic, immunohistochemical, ultrastructural, and cytogenetic characteristics of the excised mass were consistent with extraosseous ES/PNET. This is the first known reported case of extraosseous ES/ PNET of the ureter. The pathologic features and clinical management of this case, as well as a review of the literature, are presented. 相似文献
62.
Hand-assisted laparoscopic surgery (HALS) with the HandPort system: initial experience with 68 patients 总被引:37,自引:0,他引:37 下载免费PDF全文
Litwin DE Darzi A Jakimowicz J Kelly JJ Arvidsson D Hansen P Callery MP Denis R Fowler DL Medich DS O'Reilly MJ Atlas H Himpens JM Swanstrom LL Arous EJ Pattyn P Yood SM Ricciardi R Sandor A Meyers WC 《Annals of surgery》2000,231(5):715-723
OBJECTIVE: To evaluate the feasibility and potential benefits of hand-assisted laparoscopic surgery with the HandPort System, a new device. SUMMARY BACKGROUND DATA: In hand-assisted laparoscopic surgery, the surgeon inserts a hand into the abdomen while pneumoperitoneum is maintained. The hand assists laparoscopic instruments and is helpful in complex laparoscopic cases. METHODS: A prospective nonrandomized study was initiated with the participation of 10 laparoscopic surgical centers. Surgeons were free to test the device in any situation where they expected a potential advantage over conventional laparoscopy. RESULTS: Sixty-eight patients were entered in the study. Operations included colorectal procedures (sigmoidectomy, right colectomy, resection rectopexy), splenectomy for splenomegaly, living-related donor nephrectomy, gastric banding for morbid obesity, partial gastrectomy, and various other procedures. Mean incision size for the HandPort was 7.4 cm. Most surgeons (78%) preferred to insert their nondominant hand into the abdomen. Pneumoperitoneum was generally maintained at 14 mmHg, and only one patient required conversion to open surgery as a result of an unmanageable air leak. Hand fatigue during surgery was noted in 20.6%. CONCLUSIONS: The hand-assisted technique appeared to be useful in minimally invasive colorectal surgery, splenectomy for splenomegaly, living-related donor nephrectomy, and procedures considered too complex for a laparoscopic approach. This approach provides excellent means to explore, to retract safely, and to apply immediate hemostasis when needed. Although the data presented here reflect the authors' initial experience, they compare favorably with series of similar procedures performed purely laparoscopically. 相似文献
63.
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. 总被引:10,自引:0,他引:10
S E Jones J Erban B Overmoyer G T Budd L Hutchins E Lower L Laufman S Sundaram W J Urba K I Pritchard R Mennel D Richards S Olsen M L Meyers P M Ravdin 《Journal of clinical oncology》2005,23(24):5542-5551
PURPOSE: This randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen. PATIENTS AND METHODS: Patients (n = 449) were randomly assigned to receive either docetaxel 100 mg/m2 (n = 225) or paclitaxel 175 mg/m2 (n = 224) on day 1, every 21 days until tumor progression, unacceptable toxicity, or withdrawal of consent. RESULTS: In the intent-to-treat population, both the median overall survival (OS, 15.4 v 12.7 months; hazard ratio [HR], 1.41; 95% CI, 1.15 to 1.73; P = .03) and the median time to progression (TTP, 5.7 months v 3.6 months; HR, 1.64; 95% CI, 1.33 to 2.02; P < .0001) for docetaxel were significantly longer than for paclitaxel, and the overall response rate (ORR, 32% v 25%; P = .10) was higher for docetaxel. These results were confirmed by multivariate analyses. The incidence of treatment-related hematologic and nonhematologic toxicities was greater for docetaxel than for paclitaxel; however, quality-of-life scores were not statistically different between treatment groups over time. CONCLUSION: Docetaxel was superior to paclitaxel in terms of OS and TTP. ORR was higher for docetaxel. Hematologic and nonhematologic toxicities occurred more frequently in the docetaxel group. The global quality-of-life scores were similar for both agents over time. 相似文献
64.
A 29-yr old woman developed urticaria pigmentosa which subsequently progressed through systemic mastocytosis to Philadelphia chromosome negative (Ph neg) chronic myelogenous leukemia (CML) with t(8;17). Further cytogenetic evolution occurred at the time of transformation to the aggressive phase of the disease. Unlike Ph-positive CML, chromosome number 9 was not involved, nor was the breakpoint cluster region located at band 22q11. This clearly separates this case from other Ph-negative CML patients who do have involvement of 9q34 or the breakpoint cluster region. Since this is the first case of its type to be reported with cytogenetic abnormalities, the clinical relevance of the unique chromosomal rearrangement t(8;17)(p11;q25) in the setting of systemic mastocytosis is unclear. Additional cases need to be reported to determine if this genetic rearrangement is a nonrandom marker of leukemia evolving in a setting of malignant mast cell disease. 相似文献
65.
Treatment options in androgen-independent prostate cancer 总被引:4,自引:0,他引:4
Metastatic prostate cancer is a leading cause of cancer-related death in men. Although most patients will respond to androgen ablation as initial systemic therapy, nearly all patients will develop androgen-independent prostate cancer (AI CaP) and will succumb to the disease. Advances in molecular biology have demonstrated mutations in and persistent expression of the human androgen receptor in metastatic disease. Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy. Presently, the six general treatment options available for AI CaP are best supportive care, radiation therapy, radioisotopes, secondline hormonal therapy, chemotherapy (single agent or combination), and investigational therapies such as monoclonal antibodies, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, and antiangiogenesis agents, among others. None of these modalities have produced durable remissions, although some have demonstrated palliative benefit. The next generation of clinical trials should not consist of futile hormonal manipulations or repetitive chemotherapy. Therapeutic strategies aimed at circumventing molecular blocks to cell death or targeting unique cancer molecules and genes will be more likely to improve quality of life and longevity. Furthermore, the aggressive use of palliative care will ensure effective caring for patients and the healing of families in the absence of cure. 相似文献
66.
Wei G Antonescu CR de Alava E Leung D Huvos AG Meyers PA Healey JH Ladanyi M 《Cancer》2000,89(4):793-799
BACKGROUND: The primary genetic alteration in > 95% of Ewing sarcomas (ES) is a specific fusion of EWS with FLI1 or ERG. Secondary genetic alterations possibly involved in progression of ES are not well understood. A recent study found loss of the negative cell cycle regulator gene INK4A in 8 of 27 ES samples (30%). To confirm these findings and evaluate their prognostic significance, the authors studied INK4A deletion in 41 ES samples from 39 patients. METHODS: Using Southern blot analysis with an INK4A p16 cDNA probe, the intensity of the INK4A bands in ES DNA samples was normalized to that of a control probe and compared with nondeleted control DNA; > 50% signal reduction was scored as evidence of deletion. All ES tumor DNA samples previously were confirmed to have EWS rearrangements on the same Southern blots, using a cDNA probe spanning the EWS breakpoint region. RESULTS: Tumors from 7 patients (18%) showed INK4A deletion independent of disease stage (localized or metastatic) or sample source (primary tumor or metastasis). INK4A was a strong negative factor for disease specific survival in univariate analysis (P = 0.001) and in multivariate analysis including stage (relative risk = 6; P = 0.001). CONCLUSIONS: INK4A deletions appear to be the most frequent secondary molecular genetic alteration found to date in ES. Their possible clinical usefulness in identifying a subset of ES patients with poor prognosis merits systematic prospective analysis. [See related article on pages 783-92.] Copyright 2000 American Cancer Society. 相似文献
67.
Laura A. Sena Rajendra Kumar David E. Sanin Elizabeth A. Thompson D. Marc Rosen Susan L. Dalrymple Lizamma Antony Yuhan Yang Carolina Gomes-Alexandre Jessica L. Hicks Tracy Jones Kiara A. Bowers Jillian N. Eskra Jennifer Meyers Anuj Gupta Alyza Skaist Srinivasan Yegnasubramanian Jun Luo W. Nathaniel Brennen Sushant K. Kachhap Emmanuel S. Antonarakis Angelo M. De Marzo John T. Isaacs Mark C. Markowski Samuel R. Denmeade 《The Journal of clinical investigation》2022,132(23)
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), termed bipolar androgen therapy (BAT), can result in tumor regression and clinical benefit for patients with castration-resistant prostate cancer. However, predictors and mechanisms of response and resistance have been ill defined. Here, we show that growth inhibition of prostate cancer models by SPA required high androgen receptor (AR) activity and were driven in part by downregulation of MYC. Using matched sequential patient biopsies, we show that high pretreatment AR activity predicted downregulation of MYC, improved clinical response, and prolonged progression-free and overall survival for patients on BAT. BAT induced strong downregulation of AR in all patients, which is shown to be a primary mechanism of acquired resistance to SPA. Acquired resistance was overcome by alternating SPA with the AR inhibitor enzalutamide, which induced adaptive upregulation of AR and resensitized prostate cancer to SPA. This work identifies high AR activity as a predictive biomarker of response to BAT and supports a treatment paradigm for prostate cancer involving alternating between AR inhibition and activation. 相似文献
68.
Viljoen M Karlsson MO Meyers TM Gous H Dandara C Rheeders M 《European journal of clinical pharmacology》2012,68(4):339-347
Objective
To investigate the influence of CYP2B6 516G>T polymorphism, as a covariate, and of interoccasion variability (IOV) on the oral clearance (CL/F) of efavirenz (EFV) in treatment-naïve black South African children over a period of 24 months post-antiretroviral therapy (ART) initiation.Methods
HIV-infected black children (n?=?60, aged 3–16 years), with no prior exposure to ART, eligible to commence ART and attending an outpatient clinic were enrolled into this study. Blood samples were taken at mid-dose interval at 1, 3, 6, 12, 18 and 24 months post-ART initiation. EFV plasma samples were determined with an adapted and validated LC/MS/MS method. Genotyping of the CYP2B6 G516T single nucleotide polymorphism (SNP) was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). NONMEM was used for the population pharmacokinetic modelling.Results
EFV concentrations below 1 μg/mL accounted for 18% (116/649), EFV concentrations >4 μg/mL accounted for 29.5% (192/649) and concentrations within the therapeutic range (1–4 μg/mL) represented 52.5% (341/649) of all the samples determined. The covariates age, weight and CYP2B6 G516Tgenotype were included in the final model with population estimates for CL/F determined as 2.46, 4.60 and 7.33 L/h for the T/T, G/T and G/G genotype groups respectively.Conclusions
The inclusion of both age and weight to predict accurate EFV CL values for the respective genotype groups within this paediatric population was required, whereas the addition of gender and body surface area did not improve the predictions. The importance of introducing IOV in a PK model for a longitudinal study with sparsely collected data was again highlighted by this investigation.69.
Kevin B. Teuscher Somenath Chowdhury Kenneth M. Meyers Jianhua Tian Jiqing Sai Mayme Van Meveren Taylor M. South John L. Sensintaffar Tyson A. Rietz Soumita Goswami Jing Wang Brian C. Grieb Shelly L. Lorey Gregory C. Howard Qi Liu William J. Moore Gordon M. Stott William P. Tansey Taekyu Lee Stephen W. Fesik 《Proceedings of the National Academy of Sciences of the United States of America》2023,120(1)
70.